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Mutant mice lacking both cyclin-dependent kinase (CDK) inhibitors p18Ink4c and p27Kip1 develop a tumor
spectrum reminiscent of human multiple endocrine neoplasia (MEN) syndromes. To determine how p18 and
p27 genetically interact with Men1, the tumor suppressor gene mutated in familial MEN1, we characterized
p18-Men1 and p27-Men1 double mutant mice. Compared with their corresponding single mutant littermates,
the p18/; Men1/ mice develop tumors at an accelerated rate and with an increased incidence in the
pituitary, thyroid, parathyroid, and pancreas. In the pituitary and pancreatic islets, phosphorylation of the
retinoblastoma (Rb) protein at both CDK2 and CDK4/6 sites was increased in p18/ and Men1/ cells and
was further increased in p18/; Men1/ cells. The remaining wild-type Men1 allele was lost in most tumors
from Men1/ mice but was retained in most tumors from p18/; Men1/ mice. Combined mutations of
p27/ and Men1/, in contrast, did not exhibit noticeable synergistic stimulation of Rb kinase activity, cell
proliferation, and tumor growth. These results demonstrate that functional collaboration exists between p18
and Men1 and suggest that menin may regulate additional factor(s) that interact with p18 and p27 differently.
Retinoblastoma family proteins, Rb, p107, and p130, col-
laboratively regulate G1 cell cycle progression and maintain
cells at quiescent G0 state (34). When present in hypophos-
phorylated states, these proteins bind to E2F transcription
factors and repress the transcription of various E2F target
genes, thereby preventing S phase entry. Mitogen-induced ex-
pression of D-type cyclins activates cyclin D-dependent CDK4
and CDK6 kinases, leading to phosphorylation and functional
inactivation of Rb proteins. Conversely, binding with an INK4
protein or depriving cyclin D synthesis inhibits CDK4/6,
retaining Rb proteins in their growth-suppressive states and
preventing the G1-to-S transition. Functional inactivation of
this pathway, consisting of INK4-cyclin D/CDK4/6-Rb-E2F,
is a common event for the development of most types of
cancer (29).
A long-standing puzzle from the studies of mice is that,
despite the fundamental function of the Rb pathway in cell
cycle control and frequent mutations in many different types of
human cancers, mice with mutations impairing the Rb pathway
develop tumors predominantly in neuroendocrine organs.
Characteristic intermediate lobe pituitary tumors develop in
mice heterozygous for Rb (12, 17), chimeric for Rb/ (19, 25,
35), and deficient for CDK inhibitors p18Ink4c (8, 9, 16) and
p27Kip1 (7, 15, 24). Furthermore, mice with compounded mu-
tations in both Rb1 and p53 genes develop tumors with high
penetrance in the pituitary, pancreatic islets, and thyroid (5, 10,
35). More strikingly, mice carrying a INK4-insensitive muta-
tion (R24C) in CDK4 or mice carrying simultaneous deletions
of both the CDK inhibitors p18Ink4c and p27Kip1 develop tu-
mors in multiple endocrine organs, including the pituitary,
thyroid, parathyroid, adrenal glands, pancreas, and testis (9,
30), a tumor spectrum that is congruous with the human mul-
tiple endocrine neoplasia (MEN) syndrome. Many major tu-
mor types which sustain frequent mutations targeting the genes
on the Rb pathway in humans, such as glioblastoma and cancer
of the breast, lung, skin, bone, head, and neck, are rarely
observed in mice with mutations targeting the Rb pathway.
Endocrine glands include seven so-called classical tissues or
organs (pituitary, thyroid, parathyroid, pancreatic islets, adre-
nals, testes, and ovaries), as well as various other tissue systems
(e.g., lung and gastrointestinal carcinoid) that are not usually
considered endocrine glands but that contain cells that pro-
duce and secrete hormones, cytokines, and secondary messen-
gers (31). Clinical diagnoses of hereditary MEN syndromes
include the multiplicity of tumors in a given endocrine organ
and the multiplicity of endocrine organs developing tumors in
an individual. The recognition of Mendelian inheritance within
MEN syndromes has led efforts over the past decade to iden-
tify causal genes by linkage analysis and positional cloning,
including the type 1 MEN gene, Men1, which encodes a nu-
clear transcriptional regulator protein, known as menin (4).
Despite the widespread expression of menin in nearly all tis-
sues during embryonal development and in adults (32), loss of
function of the Men1 gene, perplexingly, causes a unique and
restricted pattern of endocrine tumors in both humans and
mice. Germ line mutations in Men1 predispose humans to
endocrine tumor development, predominantly in the anterior
lobe of pituitary, parathyroid, and pancreatic islet cells (21).
Likewise, mice heterozygous for Men1 developed multiple
endocrine tumors with a spectrum very similar to human
Men1 kindred (2, 6). Both the biochemical function of me-
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nin and the cellular pathway that Men1 regulates are cur-
rently under investigation. In particular, how Men1 may
genetically interact with other genes involved in tumor sup-
pression has not been examined.
Development of multiple neuroendocrine tumors in p18-p27
double mutant mice led us to determine how Men1 genetically
interacts with p18 and p27. These genetic, histological, and
pathological studies revealed that p18, but not p27, genetically
collaborates with Men1 to suppress the development of multi-
ple types of endocrine tumors.
MATERIALS AND METHODS
Mouse strains. The generation of p18 and Men1 mutant mice and conditions
for genotyping were described previously (6, 8), and both p18 and Men1 mutant
mice have been backcrossed into, and maintained on, a C57BL/6 background.
Mice deficient for p18 were bred with mice heterozygous for Men1 to create
doubly heterozygous mice. Mice heterozygous for both p18 and Men1 were then
intercrossed to generate all of the genotypes analyzed in this study. Animals were
genotyped by PCR and monitored as described previously. Cohorts were housed
and analyzed in a common setting, and littermate controls were used for all
experiments as indicated below. All mice were sacrificed and subjected to com-
plete necropsy as age-matched controls. The mice were mainly divided into five
groups based on different time points (3 months, 6 to 9 months, 9 to 12 months,
12 to 16 months, and 16 to 22 months of age) (Table 1). Most groups of mice
younger than 1 year of age had at least three mice for each genotype, except for
a few groups from wild-type and p27/ mice, some of which contained two mice.
Histopathology and IHC. Tissues of most organs were removed, fixed in 10%
neutral buffered formalin, and examined histologically by two pathologists after
hematoxylin-eosin staining. Lesions were photographed, and additional sections
were taken for immunohistochemical analyses. Immunohistochemistry (IHC)
was performed as described previously (1). To measure proliferating and mitotic
cells, sections were blocked with normal goat serum in phosphate-buffered saline
and incubated with either a polyclonal antibody against mitosis-specific phos-
phorylated histone H3 (5 g ml1; Upstate Biotechnology) or a polyclonal
antibody against Ki67 (NCL-Ki67 at a dilution of 1:1,000; Novocastra Labora-
tories) for 1 h and with biotin-conjugated secondary antibody (Vector Labora-
tories) for 30 min. Other primary antibodies used were as follows: to insulin
(Dako Cytomation), to phospho-Rb(Ser608) (Cell Signaling), to phospho-
Rb(Thr821) (Biosource), and to menin (Bethyl). Immunocomplexes were de-
tected using the Vectastain ABC alkaline phosphatase kit according to the
manufacturer’s instructions (Vector Laboratories) or using rhodamine-conju-
gated secondary antibody. For apoptosis assays, terminal deoxynucleotidyltrans-
ferase-mediated dUTP-biotin nick end labeling (TUNEL) assays were carried
out using an in situ ApopTag kit (Chemicon) according to the manufacturer’s
protocol.
LCM and loss-of-heterozygosity (LOH) analysis. Laser capture microdissec-
tion (LCM) was used to obtain pure cell populations of selected areas from
formalin-fixed, paraffin-embedded tissue sections. Ten-micrometer sections were
deparaffinized and lightly stained with hematoxylin. Using a PixCell lle Laser
Capture Microdissection system (Arcturus, Mountain View, CA), the lesions that
were clearly separated from normal tissues were isolated from the slides. Par-
ticular care was taken to avoid contamination by surrounding tissue. DNA
isolation from the microdissected tissue samples was performed as described
before (1).
Pancreatic islet size determination. Pancreatic islet size (number of cells/islet
section) was measured as previously reported (20). Briefly, islet size was deter-
mined in at least three cut sections from matched pancreatic regions of three
animals per genotype at each stage of development. Sections were more than 500
m apart from each other to avoid the overestimation of large islets in this
analysis. For pancreatic islet number counting, the whole pancreas was dissected
together with the surrounding spleen and stomach tissue to preserve the shape of
the pancreas during subsequent procedures of fixation and paraffin embedding.
Dissected pancreases were flatly embedded, with similar orientations and max-
imized surface areas showing. Islet number per section was determined from
age-matched pancreases of three animals per genotype and averaged from at
least six sections (two each from the top, the center, and the bottom of the
pancreas).
RESULTS
p18 collaborates with Men1 in tumor suppression. Men1/
mice die in utero (between embryonic day 11.5 to 13.5), and
Men1/ mice develop endocrine tumors later in their life with
a spectrum similar to those in MEN1 patients (2, 6). While
conditional alleles have been generated to allow tissue-specific
homozygous deletion of Men1, we performed our initial studies
in Men1/ mice to gain an unbiased assessment of the func-
tional in vivo interaction between Men1 with p18 and p27 in
diverse tissues. To generate mice of several genotypes,
Men1/ mice were crossed with p18/ or p27/ mice. The
double-heterozygote p18/-Men1/ and p27/-Men1/
mice were mated to generate mice with the following geno-
types: p18/; Men1/, p18/; Men1/, p18/; Men1/,
p18/; Men1/, p27/; Men1/, p27/; Men1/,
p27/; Men1/, and p27/; Men1/. Genotype analysis of
more than 250 offspring did not identify any p18/ or p27/;
Men1/ double null mice, nor were there any viable p18/;
Men1/ or p27/; Men1/ embryos beyond embryonic day
15.5 (data not shown). These results indicate that homozygous
deletion of p18 or p27 did not rescue the embryonic lethality
caused by Men1 loss. p18/; Men1/, p27/; Men1/, and
Men1/ mice developed normally and did not show significant
phenotypic abnormalities at a young age (3 months) but
subsequently developed various hyperplastic and tumor phe-
notypes.
Consistent with previous reporting, histological and patho-
logical examination revealed that specific lesions developed
predominantly in multiple endocrine organs of p18, p27, and
Men1 single mutant mice, including the pituitary, thyroid, para-
thyroid, pancreas, adrenal, and testis. Compared to these sin-
gle mutant mice, tumor phenotypes in nearly all these endo-
crine organs were accelerated in double mutant p18/;
Men1/ mice but not in p27/; Men1/ mice (Table 1 and
Fig. 1) (see also Fig. 2 to 4).
p18, not p27, collaborates with Men1 to suppress both in-
termediate and anterior lobe pituitary tumors. Before 1 year
of age, 2 of 13 (15%) p18/ mice developed pituitary tumors
in the intermediate lobe. Thereafter, four of six (67%) devel-
oped intermediate lobe pituitary tumors. At similar stages, the
incidence of intermediate lobe tumor was increased to 8 of 20
(40%) and 5 of 5 (100%) in p18/; Men1/ mice (Table 1).
Although there was statistically no significant difference in
tumor incidence between these two mutant mice, intermediate
lobe tumors were detected in p18/; Men1/ mice at as early
as 3 months of age (40%; n  5) while no such tumor was
observed in p18/ mice at a similar age. In addition, patho-
logically more aggressive features (see below) were frequently
found in p18/; Men1/ tumors than in p18/ tumors (Fig.
1). These results reveal a previously unrecognized function of
Men1 in the intermediate lobe of the pituitary.
Anterior lobe pituitary tumors were not found in the p18/
mice up to 22 months of age. In Men1 heterozygotes, only 1 of
18 (6%) developed pituitary tumors in the anterior lobe at 1
year of age, a frequency that increased to 3 of 7 (43%) in mice
older than 1 year. Anterior lobe pituitary tumors were found in
20% of p18/; Men1/ mice (n  20) prior to 1 year and
80% (n  5) thereafter. In these animals, we also noted the
formation of adenomas and adenocarcinomas in both anterior
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and intermediate lobes. Although developed at similar inci-
dences, the anterior lobe pituitary tumors in the p18/;
Men1/ mice exhibited aggressive features, including hemor-
rhaging, necrosis, and invasion into adjacent tissues (Fig. 1),
that were not noted in either p18/ or Men1/ mice. This
result indicates that p18, in addition to suppressing intermedi-
ate lobe pituitary tumors, also plays a role in suppressing an-
terior lobe pituitary tumors. By contrast, the frequency of pi-
tuitary tumors did not differ significantly between p27/;
Men1/ and p27/ single mutant mice (n  12) (data not
shown). Collectively, these results demonstrate a functional
collaboration between Men1 and p18 but not between Men1
and p27 in suppression of pituitary tumors.
p18, not p27, collaborates with Men1 to suppress testis Ley-
dig cell tumors. Before 1 year of age, no testis Leydig cell
tumors were found in any mutant mice lacking p18 or p27 or in
Men1 heterozygotes. Although half of the p18 null mice (after
1 year) developed evident hyperplasia in the testis (Fig. 2A),
no Leydig cell tumors were found in p18/ mice, even in mice
2 years of age (Table 1 and Fig. 2A). When the mice aged
beyond 1 year, two of nine (22%) Men1/ mice developed
Leydig cell adenoma in the testis and three of six p18/;
Men1/ male mice (50%) developed Leydig tumors (one ad-
enoma and two adenocarcinomas; both adenocarcinomas me-
tastasized to the lung). No Leydig cell hyperplasia or tumors
were detected in p27/ mice, even in mice 2 years of age
(Table 1), nor was there any evidence that p27 loss accelerates
the Leydig tumor phenotype in Men1/ mice (Fig. 2A). These
results also provide evidence supporting a functional collabo-
ration between p18, but not p27, and Men1 in suppressing
Leydig cell tumors in the testis.
p18, not p27, collaborates with Men1 to suppress thyroid
and parathyroid tumors. Neither p18/, p27/, nor
Men1/ mice developed a significant tumor phenotype in the
thyroid up to 22 months of age. In the p18/; Men1/mice,
4 of 5 (80%) developed thyroid adenoma by the age of 22
months, while only 1 of 16 (6%) p27/; Men1/ mice devel-
oped thyroid tumors at 12 months of age (Table 1 and Fig. 2B).
Ninety percent of MEN1 patients over 40 years old have para-
thyroid tumors, making this the most common tumor of this
FIG. 1. p18, not p27, collaborates with Men1 to suppress pituitary tumors. Age-matched pituitary glands from different genotypes of mice were
microscopically examined after hematoxylin-eosin staining. Anterior lobe (A), intermediate lobe (I), neurohypophysis (N), and tumor (T) are
indicated. Note the tumors in both intermediate and anterior lobes of p18/-Men1/ pituitary.
FIG. 2. p18, not p27, collaborates with Men1 to suppress testis, thyroid, and parathyroid tumors. (A) Age-matched testis glands from different
genotypes of mice were microscopically examined after hematoxylin-eosin staining. Leydig cell hyperplasia (H) and Leydig cell tumor (T) are
indicated. (B) hematoxylin-eosin staining of thyroid (Th) and parathyroid (Pth) from different genotypes of mice at 12 months of age. Hyperplasia
(H) and tumor (T) are indicated. Frame e shows a parathyroid tumor, and frame f shows a thyroid tumor from the same p18/-Men1/ mouse
(frame d is the same area at lower magnification).
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syndrome in humans (21). In Men1/ mice, 3 of 12 (25%)
developed detectable parathyroid tumors by the age of 22
months. p18 loss alone did not result in parathyroid tumors but
increased the incidence of parathyroid adenomas from 25% in
Men1/ mice to 80% in p18/; Men1/ mice (n  5). All
parathyroid and thyroid adenomas developed concurrently in
p18/; Men1/ mice (Fig. 2B). The underlying basis for this
concurrent parathyroid and thyroid tumor formation in
p18/; Men1/ mice is not clear. As for pituitary tumor
development, p27 deficiency alone did not result in parathyroid
tumors, nor did it increase the incidence of parathyroid tumors
in Men1/ background mice (Table 1).
p18, not p27, collaborates with Men1 to suppress pancreatic
islet insulinomas. Both p18/ and Men1/ mice developed
an islet -cell tumor phenotype in the pancreas before 1 year
of age. (2, 6, 26) (Table 1). Islet tumors developed in 15% (n 
13) of p18/ and 22% (n  18) of Men1/ mice between 9
to 12 months of age; the incidence was increased to 45% (n 
20) in p18/; Men1/ mice, and the onset time was short-
ened to as early as 3 months of age (Table 1 and Fig. 2). After
12 months of age, islet tumors were found in all p18/;
Men1/ mice (n  5), compared to 33% (n  6) of p18/
mice and 43% (n  7) of Men1/ mice (Table 1). Despite
their hyperplastic or dysplastic appearance, islet tumors were
highly immunoreactive for insulin (Fig. 3A), consistent with
the -cell origin of these tumors. Detailed analysis revealed
that tumor masses were comparably enlarged in p18/;
Men1/ pancreases. Two of five insulinomas that developed
in older (12 to 22 months) p18/; Men1/ mice had features
of multifocal islet carcinomas (Fig. 3A), while no carcinomas
were found in mice of other genotypes. In contrast to these
effects from p18 mutation, loss of p27 alone did not result in
islet hyperplasia (7, 15, 24) (Table 1), nor did p27 deficiency
have any additional effects on islet hyperplasia and tumor
frequency (Table 1 and Fig. 3A).
p18, not p27, collaborates with Men1 to regulate islet cell
proliferation and size. To further examine how Men1 differ-
entially interacts with p18 and p27 in regulating pancreatic islet
 cells, we determined both the number and size of islets in
mice of different genotypes. The number of islets was increased
on the average of 43  17 per section in p18/ and 46  18
in Men1/ to 70  14 in p18/; Men1/ mice. Although p27
deletion slightly increased the number of islets from 28  7 in
wild-type mice to 34  6, p27/; Men1/ mice actually had
a decrease in the number of islets to 24  5 (Fig. 3B). The basis
for this decrease is not clear at present.
There is an evident increase in the size of islets in p18/;
Men1/ mice. There could be two different cellular mecha-
FIG. 3. p18, not p27, collaborates with Men1 to suppress insulinoma development and to regulate pancreatic  islet cell proliferation.
(A) Results of hematoxylin-eosin staining of pancreatic sections obtained from different genotypes of mice at 12 months of age are shown (top).
The islet cell carcinoma shown in frame f has been magnified in the inset. Mitotic figures (black arrows) and tumor cells invading a blood vessel
(yellow arrow) are indicated. Pancreatic sections from 12-month-old mice of the indicated genotypes were stained with an antibody to insulin
(bottom). (B) The number of pancreatic islets per section was determined as described in Materials and Methods from 12-month-old mice of the
indicated genotypes. (C) A total of 250 islets from wild-type and mutant pancreases from mice at 1 year of age were counted. Islets are categorized
into three groups, small (containing less than 40 cells), medium (containing 41 to 400 cells), and large (containing more than 400 cells), and
percentages of each group are plotted.
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nisms accounting for the increase in islet size: an increase in
the size and/or the cell number of islet  cells. Microscopic
examination did not show any visible difference in cell size. We
therefore counted the cell numbers in 250 randomly chosen
islets from mice of six different genotypes and divided them
into three groups: small (less than 40 cells per islet), medium
(40 to 400 cells), and large (more than 400 cells) islets. The
percentage of medium- and large-sized islets increased from
25%  8% and 21%  11% in p18/ mice and 22%  6%
and 26%  8% in Men1/ mice to 26%  2% and 40%  6%
in p18/; Men1/ mice, respectively (Fig. 3C). By contrast
with Men1/ mice, the p27/-Men1/ mice, while having a
slight increase in medium islets (30%  2%), had a substan-
tially decreased number of large islets (5%  1%). Altogether,
these data suggest that p18, but not p27, functionally collabo-
rates with Men1 to control  islet cell number and to suppress
insulinoma development in the pancreas.
Increased proliferation and apoptosis in pituitary and pan-
creatic tumors of p18/; Men1/ mice. To determine the
cellular basis for the functional collaboration of p18 and Men1,
we examined two cellular processes that are often deregulated
during tumor growth—cell proliferation and apoptosis. Mitotic
index, as determined by the immunostaining of anti-phospho-
histone H3 (PH3), was low at baseline in the wild-type pan-
creases and pituitaries but increased in all three single mutant
mice (Fig. 4A). Consistent with pathological analysis, there
were further substantial increases of the mitotic index in both
p18/; Men1/ pancreases and pituitaries but not in p27/;
Men1/ pancreases and pituitaries.
The increase in cell proliferation following loss of p18, p27,
and Men1 correlated with an increased level of apoptosis in the
pituitary and pancreas, as assessed by TUNEL assay. A higher
number of TUNEL-positive cells was detected in p18/;
Men1/ pancreases and pituitaries than in either p18/ or
FIG. 4. Combined p18 and Men1 mutations increased cell proliferation and apoptosis. Sections from pituitary glands and pancreases from
different genotypes of mice at 9 to 12 months of age were examined for cell proliferation by immunostaining with an antibody recognizing
phosphorylated histone H3 (A and C) and for apoptotic cell death by TUNEL assay (B and D). At least three mice for each genotype were
examined. Pancreatic islets in the top row (A) are magnified in the respective insets. Blue, cells positive for PH3; brown, cells positive in TUNEL
assay. Positive cells for PH3 and TUNEL were counted in 10 randomly chosen fields. The P value is less than 0.05 for p18/; Men1/ versus either
p18/ or Men1/ samples and larger than 0.05 for p27/; Men1/ versus either p27/ or Men1/.
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Men1/ mice (Fig. 4B). There was no detectable increase in
apoptotic cells in either p27/-Men1/ pancreases or pitu-
itaries.
p18 deficiency protects the loss of wild-type Men1 allele.
MEN1 patients typically inherit loss-of-function mutations in
the Men1 gene, and tumors arise after loss of the remaining
wild-type allele, which appears to fit the classical definition of
a “two-hit” tumor suppressor. Development of tumors from
Men1 heterozygotes offered an opportunity to address the issue
of Men1 haploinsufficiency in tumor suppression. We took two
approaches to this end: IHC of Men1 and LOH analysis of the
remaining Men1 wild-type alleles. As determined by IHC, me-
nin expression was lost in most pancreatic tumors (five of
seven) and all pituitary (three of three) tumors that we exam-
ined (Fig. 5A and C), indicating that the remaining wild-type
Men1 allele was lost in most tumor cells. In contrast, menin
protein expression was retained in most pancreatic (9 of 10)
and pituitary (5 of 6) tumors developed in p18/; Men1/
mice, suggesting that loss of the wild-type Men1 allele in
p18/; Men1/ mice is protected by p18 loss.
To further confirm this, we conducted LCM and genomic
PCR. DNA was extracted from the tumor tissues under the
microscope, and PCR-based LOH analysis was performed.
Four of five pancreatic islet tumors and three of three pituitary
tumors developed in Men1/ mice exhibited loss of the wild-
type Men1 allele and retention of the null allele, whereas all six
pancreatic tumors and three of four pituitary tumors derived
from p18/; Men1/ mice retained the wild-type Men1 allele
(Fig. 5B and C). Together, these results demonstrate that com-
plete loss of Men1 function conveys a strong growth advantage
for tumor development to the Men1/ cells but not the
p18/; Men1/ cells, and they provide additional evidence
for the notion that p18 and Men1 regulate two separate path-
ways that collaboratively suppress tumorigenesis.
Phosphorylation of Rb protein at CDK2 and CDK4/6 sites
was increased in p18/; Men1/ but not in p27/-Men1/
cells. To search for the underlying biochemical basis for the
different genetic interactions between p18, p27, and Men1, we
examined the kinase activity of CDK2 and CDK4/6, three
major targets of p18 and p27, in normal and tumor cells of
different genotypes. Taking advantage of the availability of
several well-characterized antibodies specifically recognizing
Rb proteins phosphorylated by CDK at different sites and their
suitability for immunostaining of embedded tissue samples, we
directly examined two representative organs, the pituitary and
pancreatic islet, where p18 but not p27 exhibited an evident
functional interaction with Men1. Two well-characterized
phosphorylation sites in the Rb protein, S608 phosphorylated
by CDK4 and CDK6 and T821 phosphorylated by CDK2 (14,
37), were examined. A visible increase of Rb phosphorylations
at both CDK2 site T821 and CDK4/6 site S608 were detected
in pituitaries of p18/, p27/, and Men1/ mice (Fig. 6A
and B). In pancreatic islets, p18/, p27/, and Men1/
mutations all evidently increased S608 phosphorylation of Rb,
but an increase of T821 phosphorylation was less pronounced
in all three mutants. Combined mutation of p18/ and
Men1/ substantially increased phosphorylation of Rb at both
T821 and S608 sites in both the pituitary and pancreatic islet.
FIG. 5. p18 deficiency protects loss of the wild-type Men1 allele. (A) Sections of pancreatic tumors and pituitary tumors derived from Men1/
and p18/; Men1/ mice were immunostained with an antibody against menin. Note the strong menin staining in the tumors from p18/;
Men1/ mice and very faint (or negative) menin staining in the tumors from Men1/ mice. Frames a and b, pancreatic tumors at a magnification
of 100 (inset, 400); frame c, pituitary anterior lobe tumor from Men1/ mouse at a magnification of 100 (inset, 400); frame d, pituitary
intermediate lobe and anterior lobe tumors from p18/ Men1/ mouse at a magnification of 100 (inset 400). (B) DNA extracted from the
microdissected tumors of different genotypes was amplified by PCR to detect wild-type (wt) and mutant (mt) alleles of Men1 and p18, respectively.
Lane 1, tail DNA; lanes 2 and 3, pituitary tumors; lanes 4 to 8, pancreatic tumors. (C) Summary of loss of menin expression by IHC and of wild-type
Men1 allele by PCR analysis for tumors from the pancreas and pituitary. The results are shown as the number of menin-negative staining tumors
or absence of wild-type Men1 allele divided by the number of total samples examined.
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Combined mutations of p27/ and Men1/, on the other
hand, caused no significant change of T821 phosphorylation in
either tissue type but a surprisingly evident decrease of S608
phosphorylation in both pituitary and islet (Fig. 6). Together,
these results are consistent with the pathological analyses
showing that cell proliferation and tumor growth were syner-
gistically stimulated in p18/; Men1/ tissues but were either
not enhanced (in pituitary) or actually alleviated (in islet) in
p27/; Men1/ tissues.
DISCUSSION
In this paper, we provide evidence that p18 functionally
collaborates with Men1 to suppress development of tumors in
five endocrine organs, including the pituitary, testis, thyroid,
parathyroid, and pancreatic islets. We previously reported that
loss of p18 resulted in spontaneous development of hyperplas-
tic tissues and/or tumors in the pituitary (8), and loss of both
p18 and p27 resulted in spontaneous development of hyper-
plastic tissues and/or tumors in the pituitary, adrenals, thyroid,
parathyroid, testis, and pancreas (9). These phenotypes are
reminiscent of human MEN syndrome, implicating p18 (and
p27) as an MEN gene. One puzzling difference between the
clinical manifestation of human MEN syndromes and mouse
phenotypes is that while MEN patients develop pituitary tu-
mors in the anterior lobe, nearly all pituitary tumors developed
in p18/; p27/ mice were from the intermediate lobe. Dem-
onstration of a p18 function and its functional collaboration
with Men1 in suppressing anterior lobe pituitary tumor growth
(Fig. 1) provide further support for a role of p18 in suppression
of MEN.
In all five endocrine organs, p18/; Men1/ mice devel-
oped tumors at an earlier age and with increased incidence;
these tumors are more aggressive than those found in either
p18/ or Men1/ mice, further supporting p18 as a critical
regulator of tumor progression in endocrine neoplasms. Mu-
tations in Men1 have been frequently found in familial MEN1
patients and in sporadic neuroendocrine tumors. Mutations in
the p18 gene, however, have rarely been detected in human
cancers, raising the question of whether p18 may play different
roles in endocrine tumor suppression between human and
mouse. Two lines of evidence, however, argue against this
possibility and support a function of p18 in suppressing human
tumors. p18 is haploinsufficient for tumor suppression in mice
(1), suggesting that a complete inactivation of both alleles by
classical two-hit mutational event criteria is not necessary for
tumor development. Consistent with this p18 haploinsuffi-
ciency, loss or reduced expression of p18 has been observed in
several types of human cancers, including Hodgkin lymphomas
(27), parathyroid tumors (3), hepatocellular carcinomas (23),
and medulloblastomas (33).
One surprising conclusion derived from this study is that
Men1 genetically interacts with p18 and p27 differently; while
an increased tumorigenesis is seen in five different organs in
p18/; Men1/ mice, no evidence was obtained to support a
similar functional collaboration between Men1 and p27 in sup-
pressing endocrine tumors. Men1 encodes a 76-kDa nuclear
protein (4, 18) and associates with mixed lineage leukemia
FIG. 6. Combined p18 and Men1, but not p27 and Men1, mutations stimulate pRB phosphorylation at CDK sites. Sections of normal and
tumorigenic pituitary and pancreatic islets of different genotypes of mice at 12 months of age were examined for pRb protein phosphorylation at
two CDK sites, S608 phosphorylated by CDK4 and CDK6 and T821 phosphorylated by CDK2. Counterstaining is blue, and positive staining is
brown.
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family proteins of a histone methyltransferase (HMTase) com-
plex (11, 36). Genome-wide analysis of genomic occupancy
revealed that menin can potentially regulate the expression of
a large number of target genes, possibly by recruiting HMTase
(28). A direct binding by menin and increase of histone H3
lysine 4 methylation have been demonstrated for five genes,
including HOX cluster genes HOXA9, c6, and c8 (11, 36) and,
notably, both p18 and p27 (13, 22, 28). Loss of menin is con-
versely associated with the reduction of both p18 and p27 gene
expression (13, 22).
Why, then, are the genetic results that p18 but not p27
interacts with Men1 inconsistent with the biochemical studies
illustrating that both genes are targets regulated by menin?
Loss of one allele of Men1 reduced the expression of both p18
and p27 in pancreatic islet cells as mice aged, without causing
any appreciable change to the four other CDK inhibitor genes
examined (p15, p19, p21, and p16 were not detectably ex-
pressed) (13), suggesting that, at least in pancreatic islet cells,
a differential compensation between INK4 and CIP/KIP pro-
teins is unlikely to have contributed to the different tumor
phenotypes developed in p18/; Men1/ and p27/;
Men1/ mice. The mRNA and protein levels of both p18 and
p27 were reduced to an undetectably low level in the islets of
Men1/ mice after 28 weeks (13), arguing against the possi-
bility that a differential effect of Men1 heterozygosity on p18
and p27 transcription is the explanation for the functional
collaboration of Men1 with p18 but not p27. Given the poten-
tially large number of genes regulated by menin-associated
HMTases, we speculate that another menin target gene, whose
level is affected by Men1 heterozygosity, differentially interacts
with p18 and p27. One possible scenario is that Men1 activity
may negatively regulate a factor(s) that functions in stimulating
CDK activity and that an increased expression of this factor in
Men1 mutant cells may antagonistically inhibit the increase of
CDK activity caused by p27 loss.
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